Loading stock data…
KYTX
$8.87+0.07 (+0.80%)
Market ClosedLast close May 1
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kyverna Therapeutics, Inc. in the Healthcare sector is trading at $8.87. The stock is currently 35% below its 52-week high of $13.67, remaining 26.2% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why KYTX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.87
Potential Upside
5%
Whystock Fair Value$9.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$29.60+233.7%
Range$20.00 – $33.00
Fundamentals
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$619.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.64
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.45%
Volume
Today's trading volume
533,175
Recent News
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a ... Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects
Kyverna Therapeutics (KYTX) is back in focus after unveiling positive topline data from its registrational KYSA-8 trial in stiff person syndrome, representing a key step toward a potential first-in-class autoimmune CAR T approval. See our latest analysis for Kyverna Therapeutics. The stock has whipsawed around the equity raise and trial headlines, with a 1 day share price return of minus 32.52 percent, a 90 day share price return of 37.92 percent, and a 1 year total shareholder return of...
Wall Street Set to Open Higher Wednesday as Investors Dissect Mixed Jobs Report, Look Ahead to Thursday's Inflation Data
US stocks look set to open higher in Wednesday's trading session as investors parse Tuesday's mixed